HealthStream Announces First Quarter 2021 Results
HealthStream, Inc. (HSTM) reported Q1 2021 revenues of $63.5 million, a 3% increase from Q1 2020's $61.6 million. However, operating income fell 54% to $3.3 million, and net income dropped 68% to $2.3 million, primarily due to a $3.4 million prior year adjustment. EPS declined to $0.07 from $0.22. Adjusted EBITDA rose 14% to $13.6 million. The company completed the <$2 million> acquisition of ComplyALIGN in January 2021 and anticipates 2021 revenue guidance between $245 million and $255 million.
- Revenues increased by 3% to $63.5 million in Q1 2021.
- Adjusted EBITDA rose 14% to $13.6 million in Q1 2021.
- Acquired ComplyALIGN for $2 million, enhancing healthcare solution offerings.
- Added 121,000 net new hStream subscriptions.
- Operating income fell 54% to $3.3 million compared to prior year.
- Net income decreased by 68% to $2.3 million in Q1 2021.
- EPS declined to $0.07 from $0.22 in the same quarter last year.
- Significant $3.4 million one-time adjustment impacted previous year's income.
HealthStream, Inc. (Nasdaq: HSTM), a leading provider of workforce and provider solutions for the healthcare industry, announced today results for the first quarter ended March 31, 2021.
-
Revenues of
$63.5 million in the first quarter of 2021, up3% from$61.6 million in the first quarter of 2020. -
Operating income of
$3.3 million in the first quarter of 2021, down54% from$7.2 million in the first quarter of 2020, which comparison was negatively impacted by a one-time contractual adjustment to cost of revenues in the amount of$3.4 million in the first quarter of 2020. -
Net income of
$2.3 million in the first quarter of 2021, down68% from$7.1 million in the first quarter of 2020, which comparison was negatively impacted by$2.6 million from the contractual adjustment in the first quarter of 2020 referenced above. -
Earnings per share (EPS) of
$0.07 per share (diluted) in the first quarter of 2021 compared to$0.22 in the first quarter of 2020, which was impacted by$0.08 from the contractual adjustment in the first quarter of 2020 referenced above. -
Adjusted EBITDA1 of
$13.6 million in the first quarter of 2021, up14% from$11.9 million in the first quarter of 2020. -
Completed the acquisition of ComplyALIGN, a Chicago-based healthcare technology company, on January 19, 2021, for
$2.0 million in cash. - Kevin O’Hara joined HealthStream as Senior Vice President & General Manager, Platform Solutions; Scott Fenstermacher was named Senior Vice President, Sales.
Financial Results:
First Quarter 2021 Compared to First Quarter 2020
Revenues for the first quarter of 2021 increased by
Generally accepted accounting principles (GAAP) require companies to write down beginning balances of acquired deferred revenue as part of “fair value” accounting. During the first quarter of 2021, HealthStream reported a reduction of
Operating income was
Net income was
Adjusted EBITDA was
At March 31, 2021, the Company had cash and cash equivalents and marketable securities of
Other Business Updates
At March 31, 2021, we had approximately 4.34 million contracted subscriptions to hStream™, our Platform-as-a-Service technology. hStream technology enables healthcare organizations and their respective workforces to easily connect to and gain value from the growing HealthStream ecosystem of applications, tools, and content.
On January 19, 2021, the Company acquired ProcessDATA, Ltd. (d/b/a ComplyALIGN and HospitalPORTAL), a Chicago-based healthcare technology company, for
Management Team Announcements
On January 1, 2021, Kevin O’Hara joined HealthStream as Senior Vice President & General Manager, Platform Solutions, and Scott Fenstermacher—who previously served as Vice President, Sales—was promoted to Senior Vice President, Sales. Both new members of the Company’s executive team have approximately a decade of experience at HealthStream with Mr. O’Hara’s initial tenure served from 2001 – 2011 and Mr. Fenstermacher’s tenure beginning in early 2012. In his current position, Mr. O’Hara is responsible for the growth, development, and integration of the hStream platform throughout the Company. As Senior Vice President, Sales, Mr. Fenstermacher is responsible for the sales efforts of HealthStream’s Workforce Development and Platform solutions, providing executive-level guidance and direction.
Financial Outlook for 2021
The Company is updating its guidance for 2021 for the measures set forth below, including adjusted EBITDA, a non-GAAP financial measure as defined later in this release. For a reconciliation of projected adjusted EBITDA to projected net income (loss) (the most comparable GAAP measure) for 2021, see the table included on page 10 of this release.
|
|
Full Year 2021 Guidance |
|||||||
Revenue |
|
|
|
|
|
|
|
|
|
Workforce Solutions |
|
$ |
197.0 |
|
- |
$ |
205.0 |
|
million |
Provider Solutions |
|
|
48.0 |
|
- |
|
50.0 |
|
million |
Consolidated |
|
$ |
245.0 |
|
- |
$ |
255.0 |
|
million |
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA1 |
|
$ |
40.0 |
|
- |
$ |
44.0 |
|
million |
|
|
|
|
|
|
|
|
|
|
Capital Expenditures |
|
$ |
25.0 |
|
- |
$ |
27.0 |
|
million |
1 |
Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net loss (the most comparable GAAP measure) is included later in this release. |
The Company’s guidance for 2021 as set forth above reflects the Company’s assumptions regarding, among other things, the COVID-19 pandemic as noted below, anticipated integration costs and additional investments in sales, marketing, and product development in 2021 for recently acquired companies, and estimated deferred revenue write-downs of
The Company’s financial guidance assumes that public health conditions associated with the pandemic and general economic conditions (including conditions impacting healthcare organizations) continue to improve over the course of the year, including that COVID-19 vaccines continue to be successfully distributed and perform according to current expectations and that new variants of the virus, or other unknown variants, do not further impede recovery from the pandemic.
Commenting on first quarter 2021 results, Robert A. Frist, Jr., Chief Executive Officer of HealthStream, said, “We are starting the year strong with our team managing to outpace several anticipated headwinds to produce record adjusted EBITDA in the first quarter. Moreover, we acquired ComplyALIGN, contracted 121,000 net new hStream subscriptions to our platform, and added two outstanding executives to our management team in the quarter. Our focus remains on supporting healthcare organizations in developing their workforce and improving outcomes—and I believe our success in doing that positions us for sustained growth in 2021 as reflected in our increased guidance.”
A conference call with Robert A. Frist, Jr., Chief Executive Officer, Scott A. Roberts, Chief Financial Officer and Senior Vice President, and Mollie Condra, Vice President of Investor Relations and Corporate Communications, will be held on Tuesday, April 27, 2021, at 9:00 a.m. (ET). To listen to the conference, please dial 877-647-2842 (no conference ID needed) if you are calling within the domestic U.S. or Canada. If you are an international caller, please dial 914-495-8564 (no conference ID needed). The conference may also be accessed by going to http://ir.healthstream.com/events.cfm for the simultaneous Webcast of the call, which will subsequently be available for replay. The replay telephone numbers are 855-859-2056 (conference ID #5087987) for U.S. and Canadian callers and 404-537-3406 (conference ID #5087987) for international callers.
Use of Non-GAAP Financial Measures
This press release presents adjusted EBITDA, a non-GAAP financial measure used by management in analyzing the Company’s financial results and ongoing operational performance.
In order to better assess the Company’s financial results, management believes that net income excluding the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses and before interest, income taxes, stock based compensation, depreciation and amortization, changes in fair value of non-marketable equity investments, the de-recognition of non-cash expense resulting from the PTO expense reduction in the first quarter of 2021 and the resolution of a mutual disagreement related to various elements of a past partnership which resulted in a reduction to cost of sales in the first quarter of 2020 (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash and non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. We also believe that adjusted EBITDA is useful to investors to assess the Company’s ongoing operating performance and to compare the Company’s operating performance between periods. In addition, beginning in 2021, executive bonuses are based on the achievement of adjusted EBITDA targets.
The Company has revised its definition of adjusted EBITDA to adjust for the derecognition of non-cash expense during the first quarter of 2021 related to the reduction of PTO expense resulting from modifications to the Company’s PTO policy. The Company has included an adjustment in the definition of adjusted EBITDA for the derecognition of this non-cash expense because this amount constitutes a non-cash benefit that management believes is outside of the ordinary course of the Company’s operations and is not reflective of the Company underlying operating performance.
As noted above, the definition of adjusted EBITDA includes an adjustment for the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses. Following the completion of any acquisition by the Company, the Company must record the acquired deferred revenue at fair value as defined in GAAP, which may result in a write-down of deferred revenue. If the Company is required to record a write-down of deferred revenue, it may result in lower recognized revenue, operating income, and net income in subsequent periods. Revenue for any such acquired business is deferred and is typically recognized over a one-to-two year period following the completion of any particular acquisition, so our GAAP revenues for this one-to-two year period will not reflect the full amount of revenues that would have been reported if the acquired deferred revenue was not written down to fair value. Management believes that including an adjustment in the definition of adjusted EBITDA for the impact of the deferred write-downs associated with fair value accounting for acquired businesses provides useful information to investors because the deferred revenue write-down recognized in periods after an acquisition may, given the nature of this non-cash accounting impact, cause our GAAP financial results during such periods to not fully reflect our underlying operating performance and thus adjusting for this amount may assist in comparing the Company’s results of operations between periods.
Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and have limitations as analytical tools.
This non-GAAP financial measure should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP. Investors are encouraged to review the reconciliations of adjusted EBITDA to net income (loss) (the most comparable GAAP measure), which is set forth below in this release.
About HealthStream
HealthStream (Nasdaq: HSTM) is dedicated to improving patient outcomes through the development of healthcare organizations’ greatest asset: their people. Our unified suite of solutions is contracted by healthcare organizations across the U.S. for workforce development, training & learning management, nurse & staff scheduling, clinical education, credentialing, privileging, provider enrollment, performance assessment, and managing simulation-based education programs. HealthStream’s corporate office is in Nashville, Tennessee. For more information, visit http://www.healthstream.com or call 800-521-0574.
HEALTHSTREAM, INC. Condensed Consolidated Statements of Income (In thousands, except per share data) (Unaudited) |
||||||||
|
|
Three Months Ended |
|
|||||
|
|
March 31, 2021 |
|
|
March 31, 2020 |
|
||
Revenues, net |
|
$ |
63,468 |
|
|
$ |
61,572 |
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
Cost of revenues (excluding depreciation and amortization) |
|
|
21,237 |
|
|
|
20,359 |
|
Product development |
|
|
9,361 |
|
|
|
7,468 |
|
Sales and marketing |
|
|
8,924 |
|
|
|
9,188 |
|
Other general and administrative expenses |
|
|
11,493 |
|
|
|
9,864 |
|
Depreciation and amortization |
|
|
9,153 |
|
|
|
7,449 |
|
Total operating costs and expenses |
|
|
60,168 |
|
|
|
54,328 |
|
|
|
|
|
|
|
|
|
|
Operating income |
|
|
3,300 |
|
|
|
7,244 |
|
|
|
|
|
|
|
|
|
|
Other (loss) income, net |
|
|
(87 |
) |
|
|
1,706 |
|
|
|
|
|
|
|
|
|
|
Income before income tax provision |
|
|
3,213 |
|
|
|
8,950 |
|
Income tax provision |
|
|
922 |
|
|
|
1,858 |
|
Net income |
|
$ |
2,291 |
|
|
$ |
7,092 |
|
|
|
|
|
|
|
|
|
|
Net income per share: |
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.07 |
|
|
$ |
0.22 |
|
Diluted |
|
$ |
0.07 |
|
|
$ |
0.22 |
|
|
|
|
|
|
|
|
|
|
Weighted average shares of common stock outstanding: |
|
|
|
|
|
|
|
|
Basic |
|
|
31,504 |
|
|
|
32,334 |
|
Diluted |
|
|
31,526 |
|
|
|
32,357 |
|
|
|
|
|
|
|
|
|
|
HEALTHSTREAM, INC. Condensed Consolidated Balance Sheets (In thousands) (Unaudited) |
||||||||
|
|
March 31, |
|
|
December 31, |
|
||
|
|
2021 |
|
|
2020 |
|
||
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
45,348 |
|
|
$ |
36,566 |
|
Marketable securities |
|
|
10,622 |
|
|
|
9,928 |
|
Accounts and unbilled receivables, net |
|
|
37,183 |
|
|
|
46,100 |
|
Prepaid and other current assets |
|
|
21,824 |
|
|
|
22,131 |
|
Total current assets |
|
|
114,977 |
|
|
|
114,725 |
|
|
|
|
|
|
|
|
|
|
Capitalized software development, net |
|
|
27,190 |
|
|
|
26,631 |
|
Property and equipment, net |
|
|
20,653 |
|
|
|
22,218 |
|
Operating lease right of use assets, net |
|
|
27,276 |
|
|
|
28,081 |
|
Goodwill and intangible assets, net |
|
|
279,447 |
|
|
|
279,155 |
|
Deferred tax assets |
|
|
974 |
|
|
|
974 |
|
Deferred commissions |
|
|
21,375 |
|
|
|
19,907 |
|
Other assets |
|
|
9,790 |
|
|
|
8,622 |
|
Total assets |
|
$ |
501,682 |
|
|
$ |
500,313 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable, accrued and other liabilities |
|
$ |
28,516 |
|
|
$ |
38,266 |
|
Deferred revenue |
|
|
88,390 |
|
|
|
81,176 |
|
Total current liabilities |
|
|
116,906 |
|
|
|
119,442 |
|
Deferred tax liabilities |
|
|
16,560 |
|
|
|
14,523 |
|
Deferred revenue, non-current |
|
|
1,518 |
|
|
|
1,603 |
|
Operating lease liability, noncurrent |
|
|
27,675 |
|
|
|
28,479 |
|
Other long-term liabilities |
|
|
2,218 |
|
|
|
2,204 |
|
Total liabilities |
|
|
164,877 |
|
|
|
166,251 |
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
Common stock |
|
|
272,001 |
|
|
|
271,784 |
|
Accumulated other comprehensive income |
|
|
235 |
|
|
|
1 |
|
Retained earnings |
|
|
64,569 |
|
|
|
62,277 |
|
Total shareholders’ equity |
|
|
336,805 |
|
|
|
334,062 |
|
Total liabilities and shareholders' equity |
|
$ |
501,682 |
|
|
$ |
500,313 |
|
HEALTHSTREAM, INC. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) |
||||||||
|
|
Three Months Ended |
|
|||||
|
|
March 31, |
|
|
March 31, |
|
||
|
|
2021 |
|
|
2020 |
|
||
Operating activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
2,291 |
|
|
$ |
7,092 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
9,153 |
|
|
|
7,449 |
|
Share-based compensation |
|
|
616 |
|
|
|
550 |
|
Amortization of deferred commissions |
|
|
2,133 |
|
|
|
2,159 |
|
Deferred income taxes |
|
|
486 |
|
|
|
500 |
|
Provision for doubtful accounts |
|
|
142 |
|
|
|
288 |
|
Loss on equity method investments |
|
|
54 |
|
|
|
11 |
|
Non-cash paid time off expense |
|
|
(1,011 |
) |
|
|
— |
|
Non-cash royalty expense |
|
|
— |
|
|
|
(3,440 |
) |
Change in fair value of non-marketable equity investments |
|
|
— |
|
|
|
(1,152 |
) |
Other |
|
|
15 |
|
|
|
47 |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts and unbilled receivables |
|
|
7,379 |
|
|
|
(4,573 |
) |
Prepaid and other assets |
|
|
(3,372 |
) |
|
|
(3,935 |
) |
Accounts payable, accrued and other liabilities |
|
|
(5,644 |
) |
|
|
(5,333 |
) |
Deferred revenue |
|
|
6,862 |
|
|
|
6,453 |
|
Net cash provided by operating activities |
|
|
19,104 |
|
|
|
6,116 |
|
|
|
|
|
|
|
|
|
|
Investing activities: |
|
|
|
|
|
|
|
|
Business combinations, net of cash acquired |
|
|
(731 |
) |
|
|
(21,421 |
) |
Changes in marketable securities |
|
|
(705 |
) |
|
|
6,595 |
|
Payments to acquire non-marketable equity investments |
|
|
(1,000 |
) |
|
|
— |
|
Purchases of property and equipment |
|
|
(1,898 |
) |
|
|
(1,010 |
) |
Payments associated with capitalized software development |
|
|
(5,326 |
) |
|
|
(4,068 |
) |
Net cash used in investing activities |
|
|
(9,660 |
) |
|
|
(19,904 |
) |
|
|
|
|
|
|
|
|
|
Financing activities: |
|
|
|
|
|
|
|
|
Taxes paid related to net settlement of equity awards |
|
|
(399 |
) |
|
|
(373 |
) |
Repurchases of common stock |
|
|
— |
|
|
|
(9,876 |
) |
Payment of cash dividends |
|
|
(12 |
) |
|
|
(30 |
) |
Net cash used in financing activities |
|
|
(411 |
) |
|
|
(10,279 |
) |
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
(251 |
) |
|
|
(46 |
) |
Net increase (decrease) in cash and cash equivalents |
|
|
8,782 |
|
|
|
(24,113 |
) |
Cash and cash equivalents at beginning of period |
|
|
36,566 |
|
|
|
131,538 |
|
Cash and cash equivalents at end of period |
|
$ |
45,348 |
|
|
$ |
107,425 |
|
Reconciliation of GAAP to Non-GAAP Financial Measures(1) (In thousands) (Unaudited) |
||||||||
|
|
Three Months Ended March 31, |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
GAAP net income |
|
$ |
2,291 |
|
|
$ |
7,092 |
|
Deferred revenue write-down |
|
|
1,622 |
|
|
|
144 |
|
Interest income |
|
|
(18 |
) |
|
|
(594 |
) |
Interest expense |
|
|
32 |
|
|
|
25 |
|
Income tax provision |
|
|
922 |
|
|
|
1,858 |
|
Stock based compensation expense |
|
|
616 |
|
|
|
550 |
|
Depreciation and amortization |
|
|
9,153 |
|
|
|
7,449 |
|
Non-cash paid time off expense |
|
|
(1,011 |
) |
|
|
— |
|
Change in fair value of non-marketable equity investments |
|
|
— |
|
|
|
(1,152 |
) |
Non-cash royalty expense |
|
|
— |
|
|
|
(3,440 |
) |
Adjusted EBITDA |
|
$ |
13,607 |
|
|
$ |
11,932 |
|
(1) |
This press release contains certain non-GAAP financial measures, including adjusted EBITDA, which is used by management in analyzing its financial results and ongoing operational performance. |
Reconciliation of GAAP to Non-GAAP Financial Measures Financial Outlook for 2021 (In thousands) (Unaudited) |
||||||||
|
|
Low |
|
|
High |
|
||
Net income (loss) |
|
$ |
(1,900 |
) |
|
$ |
600 |
|
Deferred revenue write-down |
|
|
4,300 |
|
|
|
4,000 |
|
Interest income |
|
|
(100 |
) |
|
|
(100 |
) |
Interest expense |
|
|
100 |
|
|
|
100 |
|
Income tax provision (benefit) |
|
|
(500 |
) |
|
|
300 |
|
Stock based compensation expense |
|
|
2,500 |
|
|
|
2,800 |
|
Depreciation and amortization |
|
|
36,600 |
|
|
|
37,300 |
|
Non-cash paid time off expense |
|
|
(1,000 |
) |
|
|
(1,000 |
) |
Adjusted EBITDA |
|
$ |
40,000 |
|
|
$ |
44,000 |
|
This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2021 as well as the anticipated impact of the COVID-19 pandemic on our financial results, that involve risks and uncertainties regarding HealthStream. These statements are based upon management’s beliefs, as well as assumptions made by and data currently available to management. This information has been, or in the future may be, included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by the forward-looking statements, including, without limitation, as the result of developments related to the COVID-19 pandemic, including, without limitation, related to the length and severity of the pandemic; the timing and availability of medical treatments and vaccines with respect to COVID-19; the timing and effectiveness of the ongoing rollout of currently available vaccines; the spread of potentially more contagious and/or virulent forms of the virus; business and economic conditions resulting from the pandemic; the impact on the pandemic on healthcare organizations; measures we are taking to respond to the pandemic; and the impact of governmental action and regulation in connection with the pandemic (including the CARES Act); as well as risks referenced in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed on February 25, 2021, and in the Company’s other filings with the Securities and Exchange Commission from time to time. Consequently, such forward-looking information should not be regarded as a representation or warranty or statement by the Company that such projections will be realized. Many of the factors that will determine the Company’s future results are beyond the ability of the Company to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. The Company undertakes no obligation to update or revise any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005765/en/
FAQ
What were HealthStream's Q1 2021 revenues?
How did HealthStream's net income change in Q1 2021?
What is the earnings per share for HSTM in Q1 2021?
What is the outlook for HealthStream's 2021 revenue?